Trial Profile
An Open-label, Single Administration Study to Characterize the Local Duration of Exposure of Triamcinolone Acetonide From FX006 in Patients With Osteoarthritis (OA) of the Knee
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Jan 2024
Price :
$35
*
At a glance
- Drugs Triamcinolone (Primary)
- Indications Osteoarthritis
- Focus Pharmacokinetics
- Sponsors Flexion Therapeutics; Pacira BioSciences
- 25 Mar 2015 According to a Flexion Therapeutics media release, positive data was reported from in study in 2014.
- 03 Nov 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 08 May 2014 Top-line data are expected during the second quarter of 2014, according to a Flexion Therapeutics media release.